Anne Grünewald
Anne Grünewald, PhD
Research section leader
Phone number:+49 451 3101 8201

Current Position:

Group leader ‘Mitochondrial function in movement disorders’

Research focus:

Mitochondrial function studies in human cellular models of Parkinson’s disease

Education & Scientific training

Education:

09/2000 – 02/2005 Studies of Biotechnology at the University of Applied Sciences Jena

04/2004 – 02/2005 Diploma thesis; University of Göttingen, European Neuroscience Institute, Neuroplasticity Group (Head: Prof. S. Sigrist)
Von transpositions-induzierter DGluR-GFP-Markierung zum In vivo – Imaging aktivitätsabhängiger Langzeitveränderungen der neuromuskulären Junction von Drosophila melanogaster“
Master of Science (Dipl.-Ing., FH)

07/2000 – 07/2003 Doctoral thesis; University of Lübeck, Department of Neurology, Section of Clinical and Molecular Neurogenetics (Head: Prof. C. Klein)
„Molecular characterisation of SGCE-associated myoclonus-dystonia and PINK1-associated Parkinson’s disease”
PhD (Dr. rer. nat.)


Scientific training:

06/2000 – 09/2000 INNOVENT e.V., Department of Biomaterials, supervised by Dr. S. Möller
Surface coating of metals with biopolymers

07/2000 – 09/2002 INNOVENT e.V., Department of Biomaterials, supervised by Dr. S. Möller
Optimization of an assay for phosphate detection and design of a practical course for trainees in biology

04/2003 – 08/2003 Centre National de la Recherche Scientifique, Institute of Functional Genomics (Montpellier, France), supervised by Dr. P. Marin
Search for interaction partners of the metabotropic glutamate receptor 7b (mGluR7b)

04/2005 – present University of Lübeck, Department of Neurology, Section of Clinical and Molecular Neurogenetics, supervised by Prof. C. Klein
Impact of mutations in PD-associated genes on mitochondrial function, genome integrity and morphology

04/2006 – 06/2006 Erasmus University Medical Center, Department of Clinical Genetics (Rotterdam, Netherlands), supervised by Prof. V. Bonifati
Expression analysis of the PTEN-induced putative kinase 1 gene (PINK1) in Parkinson’s disease patients with PINK1 mutation

06/2007 – 02/2008 University College London, Royal Free University and Medical School, Department of Clinical Neurosciences (London, UK), supervised by Prof. A.H.V. Schapira
Investigation of the mitochondrial function in fibroblast cultures from Parkinson’s disease patients with PINK1 mutations

02/2010 – 04/2010 University of Sydney, Kolling Institute of Medical Research, Neurogenetics Group (Sydney, Australia), supervised by Prof. C. Sue
Investigation of ATP synthesis rates in fibroblasts from Parkinson’s disease patients with Parkin mutations
09/2012 – 08/2013 Newcastle University, Mitochondrial Research Group (Newcastle upon Tyne, UK), supervised by Prof. D. Turnbull
The role of mitochondrial DNA mutations in neurodegenerative diseases

Awards & Memberships

Awards:

2003 Travel grant from the German Academic Exchange service (DAAD)
2007 Scholarship from the German Academic Exchange Service (DAAD)
2010 Travel grant from the Boehringer Ingelheim Foundation
2010 Travel grant from the German Academic Exchange Service (DAAD)
2011 Travel grant from the GlaxoSmithKline Foundation
2012 Travel grant from the Felgenhauer Foundation (German Society of Neurology)
2012 Travel grant from the German Academic Exchange Service (DAAD)
2012 Postdoctoral fellowship from the German Academic Exchange Service (DAAD) (declined)
2012 Research fellowship from the German Research Foundation (DFG)

Memberships:

American Society of Neurology
Movement Disorders Society (MDS)

Research Funding

Title: “Impact of mutations in Parkin on mitochondrial function and morphology”
Principal Investigator: Anne Grünewald, PhD
Intramural funding
Type: Research Grant
Funding period: January 2010 – December 2011
Amount: 75,000 €


Title: “The role of Parkin in mitochondrial function and morphology“
Principal Investigator: Anne Grünewald, PhD
Agency: German Research Foundation (DFG)
Type: Research Grant
Funding period: June 2011 – May 2011
Amount: 95,000 €


Title: “Abundance and cellular localization of wildtype and mutant SGCE in human skin fibroblasts and induced pluripotent stem cell-derived neurons”
Principal Investigator: Anne Grünewald, PhD
Agency: Dystonia Medical Research Foundation (DMRF)
Type: Research Grant
Funding period: January 2011 – December 2012
Amount: 76,000 €


Title: “The role of mitochondria in monogenic Parkinson’s disease”
Intramural funding
Type: Research Grant
Funding period: January 2012 – December 2014
Amount: 75,000 €


Title: “The role of the PINK1/Parkin pathway in the regulation of mitophagy”
Principal Investigator: Anne Grünewald, PhD
Agency: Fritz Thyssen Foundation
Type: Research Grant
Funding period: February 2012 – January 2014
Amount: 125,000 €

Publications

Selection of 5 most important publications out of 20;
cumulative impact factor: 124; mean 6.5

  1. Grünewald A, Djarmati A, Lohmann-Hedrich K, Farrell K, Zeller JA, Allert N, Papengut F, Petersen B, Fung V, Sue CM, O'Sullivan D, Mahant N, Kupsch A, Chuang RS, Wiegers K, Pawlack H, Hagenah J, Ozelius LJ, Stephani U, Schuit R, Lang AE, Volkmann J, Münchau A, Klein C. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008;29:331-332.

  2. Rakovic A, Grünewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;19:3124-3137.

  3. Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AHV, Pramstaller PP, Sue CM, Klein C. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS ONE 2010;5:e12962.

  4. Wortmann SB, Vaz FM, Gardeitchik T, Vissers LELM, G. Renkema GH, Schuurs-Hoeijmakers JHM, Kulik W, Lammens M, Christin C, Kluijtmans LAJ, Rodenburg RJ, Nijtmans LGJ, Grünewald A, Klein C, Gerold JM, Spelbrink JN, Kozicz T, van Hasselt PM, Harakalova M, Kloosterman W, Barić I, Pronicka E, Kalkan Ucar S, Naess K, Singhal KK, Krumina Z, Gilissen C, van Bokhoven H, Veltman JA, Smeitink JAM, Lefeber DJ, Wevers RA, Morava E, de Brouwer APM. Mutations in SERAC1, a phospholipid remodeler at the crossroads of mitochondrial function and intracellular cholesterol trafficking, cause dystonia and deafness. Nat Genet 2012;44:797-802.

  5. Grünewald A, Arns B, Seibler P, Rakovic A, Münchau A, Ramirez A, Sue CM, Klein C. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging 2012;33:1843.e1-7.

Complete list of publications
  1. Klein C, Grünewald A, Hedrich K. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2006; 66: 1129-30; author reply 1129-1130.

  2. Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K, Grünewald A, Hilker R, Steinlechner S, Boston H, Kock N, Schneider-Gold C, Kress W, Siebner H, Binkofski F, Lencer R, Münchau A, Klein C. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;63:833-838.

  3. Grünewald A, Breedveld GJ, Lohmann-Hedrich K, Rohé CF, König IR, Hagenah J, Vanacore N, Meco G, Antonini A, Goldwurm S, Lesage S, Dürr A, Binkofski F, Siebner H, Münchau A, Brice A, Oostra BA, Klein C, Bonifati V. Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. Neurogenetics 2007;8:103-109.

  4. Djarmati A, Guzvic M, Grünewald A, Lang AE, Pramstaller PP, Simon DK, Kaindl AM, Vieregge P, Nygren AO, Beetz C, Hedrich K, Klein C. Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. Mov Disord 2007;22:1708-1714.

  5. Orth M, Djarmati A, Bäumer T, Winkler S, Grünewald A, Lohmann-Hedrich K, Kabakci K, Hagenah J, Klein C, Münchau A. Autosomal dominant myoclonus-dystonia and Tourette syndrome in a family without linkage to the SGCE gene. Mov Disord 2007;22:2090-2096.

  6. Paus S, Grünewald A, Klein C, Knapp M, Zimprich A, Janetzky B, Möller JC, Klockgether T, Wüllner U. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov Disord 2008;23:599-602.

  7. Grünewald A, Djarmati A, Lohmann-Hedrich K, Farrell K, Zeller JA, Allert N, Papengut F, Petersen B, Fung V, Sue CM, O'Sullivan D, Mahant N, Kupsch A, Chuang RS, Wiegers K, Pawlack H, Hagenah J, Ozelius LJ, Stephani U, Schuit R, Lang AE, Volkmann J, Münchau A, Klein C. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008;29:331-332.

  8. Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, Lohmann K, Klein C, Djarmati A. De novo α-Synuclein duplication as cause of sporadic early onset parkinsonism. Neurology 2008;71:1294. 

  9. Grünewald A, Gegg ME, Kock N, Taanman JW, Klein C, Schapira AVH. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology (Highlighted with a mini-review in the same issue). Exp Neurol 2009; 219:266-273.

  10. Rakovic A, Grünewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;19:3124-3137.

  11. Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AHV, Pramstaller PP, Sue CM, Klein C. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS ONE 2010;5:e12962.

  12. Rakovic A, Grünewald A (equally contributed), Voges L, Hofmann S, Orolicki S, Lohmann K, Klein C. PINK1-interacting proteins: Proteomic analysis of overexpressed PINK1. Parkinsons Dis 2011; 2011:153979.

  13. Rakovic A, Grünewald A (equally contributed), Kottwitz J, Brüggemann N, Pramstaller P, Lohmann K, Klein C. Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts. PLoS ONE 2011;6:e16746.

  14. Arif B, Grünewald A, Fatima A, Ramirez A, Ali A, Brüggemann N, Würfel J, Rolfs A, Lohmann K, Malik A, Klein C, Naz S. An Unusual Neurological Syndrome of Crawling Gait, Dystonia, Pyramidal Signs, and Limited Speech. Mov Disord 2011;26:2279-2283.

  15. Abramov AY, Gegg ME, Grünewald A, Wood NW, Klein C, Schapira AHV. Bioenergentic consequences of PINK1 mutations in Parkinson disease. PLoS ONE 2011; 6:e25622.

  16. Kumar KR, Djarmati-Westenberger A, Grünewald A. The expanding field of Parkinson’s disease genetics: Review. Semin Neurol 2011;31:433-440.

  17. Grünewald A, Arns B, Seibler P, Rakovic A, Münchau A, Ramirez A, Sue CM, Klein C. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging 2012;33:1843.e1-7.

  18. Wortmann SB, Vaz FM, Gardeitchik T, Vissers LELM, G. Renkema GH, Schuurs-Hoeijmakers JHM, Kulik W, Lammens M, Christin C, Kluijtmans LAJ, Rodenburg RJ, Nijtmans LGJ, Grünewald A, Klein C, Gerold JM, Spelbrink JN, Kozicz T, van Hasselt PM, Harakalova M, Kloosterman W, Barić I, Pronicka E, Kalkan Ucar S, Naess K, Singhal KK, Krumina Z, Gilissen C, van Bokhoven H, Veltman JA, Smeitink JAM, Lefeber DJ, Wevers RA, Morava E, de Brouwer APM. Mutations in SERAC1, a phospholipid remodeler at the crossroads of mitochondrial function and intracellular cholesterol trafficking, cause dystonia and deafness. Nat Genet 2012;44:797-802.

  19. Schmidt A, Kumar KR, Redyk K, Grünewald A, Leben M, Münchau A, Sue CM, Hagenah J, Hartmann H, Lohmann K, Christen HJ, Klein C. Two faces of the same coin: Benign familial infantile seizures and paroxysmal kinesigenic dyskinesia caused by PRRT2 mutations. Arch Neurol 2012;69:668-670.

  20. Kumar KR, Ramirez A, Kresojević N, Svetel M, Sue CM, Mazzulli JR, Alcalay RN, Krainc D, Klein C, Kostic V, Grünewald A. Characterization of Glucocerebrosidase mutations in a Serbian Parkinson’s disease population; in press.

< Go back